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Background: The long-term efficacy of infliximab (IFX) for patients with refractory ulcerative colitis (UC) is unclear.
The aim of this study was to assess the long-term outcomes of IFX treatment in patients with refractory UC.
Methods: Thirty-three patients with refractory UC who received IFX treatment at Kyoto University Hospital between
2003 and 2013 were retrospectively evaluated. IFX intensification was defined as a dose escalation (up to 10 mg/kg)
and/or shorter intervals between infusions (every 4–6 weeks).
Results: Of the 33 patients who received scheduled infusions of IFX, 24 (72.7%) achieved clinical remission within
8 weeks after initiating IFX treatment. Of these 24 responders, 17 (70.8%) experienced a relapse of UC and required IFX
intensification, and 16 (66.7%) eventually maintained clinical remission with IFX treatment, including IFX intensification.
Of the 33 patients, 6 (18.2%) underwent colectomy during IFX treatment. Multivariate regression analysis showed that a
serum C-reactive protein (CRP) concentration <5 mg/L two weeks after starting IFX was a predictor of a positive clinical
response to IFX induction therapy. No severe adverse events occurred in UC patients treated with IFX.
Conclusion: IFX intensification was necessary for long-term maintenance of remission and to prevent colectomy in
patients with refractory UC.
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Ulcerative colitis (UC) is a relapsing inflammatory
bowel disease of the colon that often requires long-term
therapy to maintain remission [1]. Although most patients
are successfully managed with mesalamine formulations,
approximately 25% of patients fail these or other therapies
and require treatment with immunomodulators, including
infliximab (IFX), cyclosporin, and/or tacrolimus, and/or
colectomy [2]. IFX (Remicade: Janssen, Malvern, PA) is a
chimeric monoclonal immunoglobulin G1 (IgG1) antibody
against tumor necrosis factor (TNF)-α that binds with
high affinity to free and membrane-bound TNF-α and
neutralizes its biologic activity [3]. In patients with UC,* Correspondence: hiropy_n@kuhp.kyoto-u.ac.jp
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unless otherwise stated.IFX downregulates TNF-α in the colonic mucosa and is
associated with reduced histologic inflammation [4].
Large randomized controlled trials examining the effects
of IFX in patients with UC, as well as several cohort stud-
ies, have reported that short- to medium-term IFX is safe
and effective for inducing and maintaining remission in
patients with UC and Crohn’s disease (CD) [1,5-10]. One
year clinical remission rates were found to be 35% in pa-
tients with UC [5] and 33% in patients with CD [10]. Some
patients with CD, however, do not respond to IFX,
whereas others experience a loss of efficacy over time or
become intolerant to the drug [11]. Some CD patients
who lose the ability to respond to IFX require more inten-
sive treatment to maintain remission, such as an IFX dose
escalation or shorter intervals between infusions [11].
Similarly, 60% of UC require IFX escalation [11-13].
The effects of immunomodulators, such as azathioprine
(AZA) and mercaptopurine (MP), on clinical outcomes inl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mission rates were reported higher in AZA-naïve UC pa-
tients treated with IFX and AZA than in patients treated
with either agent [14]. Concomitant administration of an
immunomodulator and an anti-TNF-α agent, however, is
not appropriate for long-term therapy, because a high pro-
portion of CD patients treated with an immunomodulator
experience adverse events [15]. Since the effects of com-
bined treatment with IFX and an immunomodulator on
long-term clinical outcomes in UC patients are unclear,
we retrospectively analyzed long-term clinical outcomes of
UC patients following IFX induction treatment.
Methods
Patients
This study enrolled 33 patients with refractory UC who
underwent IFX treatment at Kyoto University Hospital
from January 2003 to June 2013. UC was diagnosed based
on the result of endoscopy and pathologic examination.
IFX induction therapy, consisting of 5 mg/kg IFX at 0, 2,
and 6 weeks, was followed by scheduled maintenance IFX
treatment every 8 weeks thereafter [5]. All subjects pro-
vided informed consent. The study protocol conformed to
the Declaration of Helsinki and was approved by the Insti-
tutional Review Boards at Kyoto University Hospital.
Definitions
Refractory UC was defined as steroid-resistant, steroid-
dependent, or refractory to immunosuppressive therapies.
Steroid-resistant refractory UC was defined the lack of a
clinical response to a systemic daily dose of ≧30 mg of
prednisolone over at least 2 weeks. Steroid-dependent re-
fractory UC was defined as a failure to taper prednisolone
below 10 mg/day within 12 weeks or relapse within
12 weeks after prednisolone discontinuation. Immunosup-
pressive refractory UC was defined as the lack of a clinical
response to tacrolimus, even at trough levels of 10 to
15 ng/ml; or the lack of a clinical response to the thiopur-
ine agents AZA and MP, at the doses adjusted to achieve
white blood cell counts between 3000 and 5000/μL or 6-
thioguanine nucleotide (6-TGN) concentrations between
235 and 450 pmol/8 × 108 erythrocytes. Disease activity
of UC was evaluated according to a modified Truelove
and Witts severity Index (MTWSI) score. Patients were
categorized as either responders or nonresponders to IFX
based on global assessments by gastroenterologists within
8 weeks of IFX initiation. Clinical remission was defined
as an MTWSI score lower than 4 within 8 weeks after ini-
tiating IFX therapy. Intensification of IFX treatment was
defined as a dose escalation (up to 10 mg/kg) and/or a
shorter interval between infusions (every 4–6 weeks).
Treatment with thiopurine agents was optimized based
on serum 6-TGN concentrations, with some patients re-
quiring the addition of allopurinol to increase their serum6-TGN levels. At each examination, patients were assayed
for cytomegalovirus (CMV) infection by immunohisto-
chemistry, CMV antigenemia, and quantitative real-time
polymerase chain reaction using colonic biopsy specimens
(mucosal PCR) to detect CMV-DNA in colonic mucosa.
Concomitant CMV infection was defined as positive on at
least one of these assays, as described by the guidelines of
the European Crohn’s and Colitis Organization [16]. Serum
hemoglobin and albumin concentrations were measured at
IFX initiation, and serum C-reactive protein (CRP) concen-
trations were measured immediately (0 week) and 2 weeks
after the first administration of IFX. Mucosal healing was
defined as a Mayo endoscopic score of 0 or 1 [5].
Assessments
The long-term efficacy of IFX treatment in patients with re-
fractory UC was determined by evaluating the remission-
maintenance rate and the colectomy-free rate of the 24
responders to IFX treatment including IFX intensification.
Since mucosal healing, which is associated with reduced
rates of hospitalization and colectomy, was found to con-
tribute to long-term clinical outcomes in patients with UC,
we also evaluated the mucosal healing rate in responders to
IFX treatment. To evaluate the importance of mucosal
healing in the clinical course of IFX-treated UC patients,
we compared colectomy rates in patients who did and did
not achieve mucosal healing. Finally, we evaluated the effi-
cacy of combinations of IFX and an immunomodulator
in patients with refractory UC by comparing remission-
maintenance and the colectomy-free rates in patients
receiving combination therapy and those receiving IFX
monotherapy. Remission-maintenance and mucosal heal-
ing rates in patients who responded to IFX induction treat-
ment were evaluated at 6, 12, 24 and 36 months after IFX
initiation, whereas colectomy-free rates was evaluated at 3,
6, 12 and 36 months. Moreover, factors predictive of clin-
ical remission to IFX induction therapy were evaluated by
assessing the correlations of remission with MTWSI score,
CMV negative status, serum albumin >35 g/L at IFX initi-
ation, serum CRP concentration at IFX initiation, and CRP
concentration <5 mg/L two weeks after IFX initiation.
Statistical analysis
Continuous variables were analyzed using Student’s t-test if
normally distributed or Wilcoxon’s rank sum test if the data
were nonparametric. Categorical variables were analyzed
using Pearson’s chi-squared test or Fisher’s exact test if any
cell number was less than 5. A p level of 0.05 was consid-
ered statistically significant. The cumulative colectomy-free
and remission-maintenance rates were assessed using the
Kaplan-Meier method, and groups were compared using
the log-rank test stratified by study. Predictive factors were
analyzed by multivariate statistics. Statview software was
used for all statistical analysis.
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Patient characteristics
The 33 patients with UC consisted of 20 men and 13
women, of mean age 43.2 years (range 17-75 years) and
mean disease duration at start of IFX treatment of 7.0 years
(range, 0.5-29 years; Table 1). Their mean MTWSI score
was 9.4 points (range, 6–18 points), with all 33 patients
having moderate to severe symptoms, and their mean
Mayo endoscopic score was 2.8 points (range, 2–3 points).
Twenty patients (60.6%) had extensive colitis, with the
remaining 13 (39.4%) having left-sided colitis. Twenty-
nine patients (87.9%) were steroid-dependent or steroid-
refractory, while the other 4 patients (12.1%) were
refractory to immunomodulators such as methotrexate
and tacrolimus. Upon the initiation of IFX treatment, 29
patients (87.9%) were treated with a 5-aminosalicylic acid
formulation, 11 (33.3%) were treated with corticosteroids, 16
(48.5%) were treated with concomitant thiopurine, and 13
(39.4%) were treated with concomitant tacrolimus. Biopsy
specimens from inflammatory mucosa of 11 patients (33.3%)
were positive for CMV-DNA, with two of these eleven pa-
tients treated with anti-viral agents before starting IFX treat-
ment. Twenty-five patients (75.8%) were non-smokers and
eight (24.2%) were smokers.Clinical course of UC patents after IFX induction treatment
Of the 33 patients, 31 (93.9%) were able to continue IFX in-
duction treatment, whereas the other two (6.1%) experi-
enced adverse events requiring discontinuation of IFX
induction therapy (Figure 1A). Following the initiation ofTable 1 Demographic and clinical characteristics of
UC patients
Characteristics All patients n = 33
Sex (men/women), n (%) 20 (60.6)/13 (39.4)
Age (years)* 43.2 ± 17.4
Disease duration (years)* 7.0 ± 5.7
Modified Truelove and Witts severity index* 9.4 ± 3.2
Mayo score (endoscopy)* 2.8 ± 0.4
Extent of disease
Left-side type, n (%) 13 (39.4)
Extensive colitis, n (%) 20 (60.6)
Concomitant medications
5-ASA formulation, n (%) 29 (87.9)
Corcicosteroids, n (%) 11 (33.3)
Azathioprine/Mercaptopurine, n (%) 16 (48.5)
Tacrolimus, n (%) 13 (39.4)
Cytomegalovirus, n (%) 11 (33.3)
IFX: infliximab, 5-ASA: 5-aminosalicylic acid.
Results reported as number (%) of patients or as *mean ± standard deviation.IFX induction therapy, 24 of 31 patients (77.4%) responded
and proceeded to IFX scheduled maintenance treatment,
whereas seven (22.6%) did not respond to IFX. Of the 24
responders, seven (29.2%) maintained clinical remission
on IFX maintenance therapy, whereas 17 (70.8%) experi-
enced a relapse of UC and required IFX intensification.
IFX intensification consisted of dose escalation in two,
shortened intervals between doses in eight, and a combin-
ation of the two in seven. The median duration of IFX
maintenance treatment in 17 responders was 3.0 months
(range, 1-40 months) and their median time to relapse
after IFX induction was 3.0 months (range, 1-34 months).
After IFX intensification, 16 patients (94.1%) achieved and
maintained clinical remission, whereas one patient (5.9%)
required tacrolimus owing to failure of IFX intensification.
The remission maintenance rates 6, 12, 24 and 36 months
after IFX initiation in the 24 responders who received IFX
maintenance treatment were 100.0% (22/22), 100.0% (21/
21), 92.3% (12/13) and 90.0% (9/10), respectively. Based
on Kaplan-Meier analysis, the cumulative remission-
maintenance rate of the 24 responders to IFX mainten-
ance treatment including IFX intensification was esti-
mated to be 90.9% at 63 months (Figure 1B), indicating
the importance of IFX intensification for UC patients who
have flares during IFX maintenance treatment.
Of the 33 patients who received IFX induction treat-
ment, six (18.2%) ultimately underwent colectomy dur-
ing follow-up (Figure 1A), including four who did not
respond to IFX induction treatment and two who were
found to have colon cancer during scheduled IFX main-
tenance treatment. Based on Kaplan-Meier analysis, the
colectomy-free rate at 3, 6, 12, and 36 months after IFX
initiation were 92.9% (26/28), 88.5% (23/26), 82.6% (19/23)
and 64.3% (9/14), respectively (Figure 1C).Mucosal healing in patients that received IFX
maintenance treatment including IFX intensification
Of the 24 responders, 17 (70.8%) underwent colonic exami-
nations at a median 10.0 months (range, 1–39 months)
after IFX initiation to assess mucosal healing after achieve-
ment of clinical remission. Of these 17 patients, 13 (76.5%)
achieved mucosal healing, including 11 receiving IFX main-
tenance treatment and six receiving IFX intensification
therapy. In contrast, the remaining 4 patients (23.5%)
did not show mucosal healing, despite the absence of
clinical symptoms. Rates of mucosal healing 6, 12, 24
and 36 months after IFX initiation were 87.5% (7/8),
80.0% (8/10), 78.6% (11/14) and 81.3% (13/16), respect-
ively. None of the patients who showed mucosal healing
group underwent colectomy, whereas two of the four
patients (50.0%) who did not show mucosal healing
underwent colectomy for colon cancer, a difference that
was statistically significant (p = 0.007).
Figure 1 Clinical course and survival curves of UC patients treated with IFX. (A) Clinical course of UC patients who received IFX induction
treatment. (B) Cumulative remission maintenance rate in 24 responders to IFX maintenance treatment, including IFX intensification. (C) Cumulative
colectomy-free rate in patients who received IFX treatment during follow up.
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immunomodulator
Of the 33 patients who received IFX induction treat-
ment, 16 (48.5%) received combination therapy and 17
(51.5%) received IFX monotherapy during follow-up.
Clinical remission rates in these two groups were 75.0%
(12/16) and 70.6% (12/17), respectively. The remission
maintenance rates at 6, 12, 24 and 36 months after IFX
initiation were 66.7% (10/15), 66.7% (10/15), 58.3% (7/12)
and 37.5% (3/8), respectively, in patients who received
combination therapy, and 81.3% (13/16), 75.0% (12/16),
69.2% (9/13) and 60.0% (6/10), respectively, in patients
who received IFX monotherapy. The cumulative remission
maintenance rates were similar in the combination and
monotherapy groups (73.9% at 60 months vs 56.1% at
63 months, p = 0.74; Figure 2A). Colectomy rates in these
two groups were 11.7% (2/16) and 23.5% (4/17), respect-
ively. The colectomy-free rates 6, 12, 24 and 36 months
after IFX initiation were 91.7% (11/12), 91.7% (11/12),
90.0% (9/10) and 87.5% (7/8), respectively, in patients who
received combination therapy, and 82.4% (14/17), 76.5%
(13/17), 66.7% (8/12) and 60.0% (6/10), respectively, in pa-
tients who received IFX monotherapy. The cumulativecolectomy-free rates were similar in the combination and
monotherapy groups (91.7% at 60 months vs 66.2% at
63 months, p = 0.21; Figure 2B).
No adverse events were observed in UC patients who
received combinations of IFX and an immunomodulator,
whereas two patients treated with IFX alone experienced
infusion reactions related to IFX.
Factors associated with the clinical response to IFX
induction treatment
The demographics and clinical characteristics of patients
in the responder and nonresponder groups were similar
(Table 2). The percentage of responders with serum CRP
concentration <5 mg/L 2 weeks was significantly higher
than that of nonresponders (p = 0.006). Multivariate lo-
gistic regression analysis (Table 3) showed that serum
CRP <5 mg/L 2 weeks after initiating IFX treatment was
a positive predictor of a clinical response to IFX treat-
ment (odds ratio 8.86, p = 0.08).
Factors associated with IFX intensification
We also evaluated the clinical and demographic charac-
teristics associated with the need for IFX intensification.
Figure 2 Survival curves between in patients receiving IFX
and immunomodulators and IFX alone. (A) Cumulative
remission-maintenance rates in patients receiving combination
therapy (solid line) and IFX monotherapy (dotted line). Rates were
similar in these two groups (73.9% at 60 months vs 56.1% at
63 months, p = 0.74). (B) Cumulative colectomy-free rates in
patients receiving combination therapy (solid line) and IFX monotherapy
(dotted line). These rates were also similar (91.7% at 60 months vs 66.2%
at 63 months, p = 0.21).
Yamada et al. BMC Gastroenterology 2014, 14:80 Page 5 of 9
http://www.biomedcentral.com/1471-230X/14/80The characteristics of patients who maintained clinical
remission with IFX maintenance treatment and those
with IFX intensification were similar, except for their
Mayo endoscopic score and concomitant use of cortico-
steroids (Table 4).
Clinical outcome of UC patients with CMV reactivation
Eleven of the 33 patients (33.3%) experienced CMV re-
activation before IFX treatment, with eleven being posi-
tive for CMV-DNA in colonic tissue, three positive by
immunohistochemistry and five positive by antigenemia.
Two of these 11 patients (18.2%) were treated with anti-
viral agents before initiating IFX treatment. Of these 11patients, six patients (54.5%) achieved clinical remission
after initial IFX induction therapy, whereas five (45.5%)
did not. The induction remission rate was lower in CMV-
positive than in CMV-negative patients (54.5 vs. 81.8%), al-
though the difference was not statistically significant. Among
CMV-positive patients, the five non-responders to IFX had a
significantly higher disease activity index (MTWSI) and a
significantly higher rate of concomitant tacrolimus use at the
initiation of IFX than the six responders to IFX (Table 5), in-
dicating that CMV reactivation could affect the therapeutic
efficacy of IFX in patients with refractory UC.
Adverse events
Of the 33 patients, two (6.1%) experienced adverse events,
including anaphylactic shock and drug eruption in one pa-
tient each (Figure 1A). Anaphylactic shock occurred at the
first IFX infusion and drug eruption occurred at the sec-
ond IFX infusion. Both patients were switched from IFX
to adalimumab, with clinical remission achieved and
maintained with this agent.
Discussion
Despite the large number of UC patients treated with
IFX, limited data are available on the long-term effects
of IFX treatment for UC in clinical practice. The present
study was therefore designed to evaluate the long-term
efficacy of IFX in refractory UC patients with a median
follow-up of almost 3 years.
We found that more than half the responders to initial
IFX therapy required IFX intensification owing to symp-
tom relapse. These findings are similar to those of studies
showing high rates of IFX escalation therapy (shorter infu-
sion cycles and/or higher doses) in UC patients during
maintenance treatment [5,7,17]. The present of patients
showing a short-term response to IFX has been reported
to range from 33 to 73% [5,7-9,18]. The reason for the
relatively higher short-term response rate in our patient
cohort remains unclear, although the concomitant use of
tacrolimus in more than 30% patients receiving IFX induc-
tion therapy may have affected our results.
Our findings also showed that IFX intensification can
maintain clinical improvement in patients with refractory
UC, over a median follow-up of 1.5 years. We found that
70.8% (17/24) of the initial responders to IFX required IFX
intensification and that 87.5% (21/24) maintained clinical
remission. Additionally, all UC patients who received IFX
intensification therapy avoided colectomy, with a cumula-
tive colectomy-free rate in our 33 IFX-treated patients be-
ing 64.8% at 63 months. Previous reports have shown that
the percentage of patients with refractory UC requiring
IFX escalation ranges from 14 to 54% [7,9,17-20], although
we observed a higher percentage. Although secondary loss
of response to IFX may be owed to the generation of anti-
bodies to IFX or differences in clearance, it may also be by
Table 2 Demographic and clinical characteristics of responders and non-responders to IFX induction treatment
Characteristics Responders (n = 24) Non-responders (n = 7) p value
Sex (men/women), n (%) 16 (66.7)/8 (33.3) 3 (42.9)/4 (57.1) 0.26
Age (years) 41.8 ± 17.1 48.0 ± 17.8 0.43
Disease duration (years)* 6.5 ± 4.1 9.6 ± 9.2 0.23
Modified Truelove and Witts severity index* 9.7 ± 3.2 10.6 ± 3.4 0.57
Mayo score (endoscopy)* 2.8 ± 0.4 2.9 ± 0.3 0.58
Extent of disease
Left-side type, n (%) 12 (50.0) 1 (14.3) 0.09
Extensive colitis, n (%) 12 (50.0) 6 (85.7)
Concomitant medications
Corticoteroids, n (%) 9 (37.5) 1 (14.3) 0.25
Azathioprine/Mercaptopurine, n (%) 11 (45.8) 4 (57.1) 0.60
Tacrolimus, n (%) 8 (33.3) 4 (57.1) 0.26
Cytemegalovirus, n (%) 6 (25.0) 4 (57.1) 0.17
Serum hemoglobin level >9.8 g/dl at IFX initiation, n (%) 16 (66.7) 2 (28.6) 0.07
Serum albumin level >35 g/L at IFX initiation, n (%) 12 (50.0) 1 (14.3) 0.21
Serum CRP level <5 mg/L at 2 weeks after IFX initiation, n (%) 18 (75.0) 1 (14.3) 0.006
IFX: infliximab, CRP: C-reactive protein.
Results reported as number (%) of patients or *mean ± standard deviation.
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ation) ratios. Cesarini, et al. reported that clinical remission
was maintained by 68.3% of UC patients 52 weeks after IFX
intensification; of these patients, 36.6% had received IFX-
dose escalation and 63.4% received IFX infusions at shorter
intervals, with none receiving both [20]. In contrast, the
clinical remission rate in patients who required IFX intensi-
fication was 93.3% at week 52; of the latter, 47.0% had re-
ceived IFX-dose escalation, 11.8% received IFX infusions at
shorter intervals, and 41.2% received both higher doses of
IFX and doses at shortened intervals. These data suggested
that differences between studies in remission rates of UC
patients receiving IFX intensification may be because of dif-
ferences in the percentage of UC patients who received
both higher dose of IFX and doses at shortened intervals.
The combination of IFX and an immunomodulator has
been reported superior to IFX alone in inducing remission
in UC patients [14]. The long-term differences in clinical
outcomes, however, have not yet been confirmed. Although
the cumulative rates of remission-maintenance (73.9% atTable 3 Multivariate analysis of factors predicting clinical rem
Modified Truelove and Witts severity index
Negative for cytomegalovirus
Serum albumin level >35 g/L at IFX initiation
Serum CRP level at IFX initiation
Serum CRP level <5 mg/L at 2 weeks after IFX initiation
IFX: infliximab, IM: immunomodulator, CRP: C-reactive protein, CI: confidence interva60 months vs 56.1% at 63 months, p = 0.74) and colectomy-
free status (91.7% at 60 months vs 66.2% at 63 months, p =
0.21) were higher in patients receiving combinations of IFX
and an immunomodulator than in patients receiving IFX
monotherapy, these differences were not statistically signifi-
cant. The discrepancy between our and previous results
may be owed to differences in patient characteristics, be-
cause all patients enrolled in our study had refractory UC.
Identifying factors predictive of the efficacy of IFX in pa-
tients with refractory UC is clinically important. Among
the factors previously reported to predict clinical re-
sponses to IFX treatment in UC patients are hemoglobin
concentration, serum albumin concentration, disease ac-
tivity, normalization of serum CRP concentration after
IFX induction, and the trough of IFX [7,9,17,21-23]. We
found that serum CRP concentration <5 mg/L 2 weeks
after initiating IFX was predictive of a clinical response to
IFX in patient with refractory UC. Biomarkers such as
CRP, fecal calprotectin, and fecal lactoferrin have been re-
ported to act as surrogate markers of mucosal inflammationission in response to IFX induction therapy (5 mg/kg)







Table 4 Demographic and clinical characteristics of the patients who maintained clinical remission or experienced a
relapse of UC with IFX scheduled-maintenance treatment
Characteristics Clinical remission with
IFX maintenance (n = 7)
Relapse requiring IFX
intensification (n = 17)
p value
Sex (men/women), n (%) 5 (71.4)/2 (28.6) 11 (64.7)/6 (35.3) 0.64
Age (years)* 38.6 ± 20.7 43.1 ± 15.2 0.64
Disease duration (years)* 7.2 ± 3.5 6.8 ± 4.3 0.68
Modified Truelove and Witts severity index* 7.9 ± 3.6 10.3 ± 3.0 0.23
Mayo score (endoscopy)* 3.0 ± 0.0 2.7 ± 0.5 0.02
Extent of disease
Left-side type, n (%) 2 (28.6) 10 (58.8) 0.17
Extensive colitis, n (%) 5 (71.4) 7 (41.2)
Concomitant medications
Corticoteroids, n (%) 0 (0.0) 7 (41.2) 0.04
Azathioprine/Mercaptopurine, n (%) 4 (57.1) 9 (52.9) 0.85
Tacrolimus, n (%) 3 (42.9) 5 (29.4) 0.53
Hemoglobin >9.8 g/dl at IFX initiation, n (%) 5 (71.4) 10 (58.8) 0.56
Serum albumin >35 g/L at IFX initiation, n (%) 2 (28.6) 10 (58.8) 0.18
Serum CRP <5 mg/L at 2 weeks after IFX initiation, n (%) 6 (85.7) 12 (70.6) 0.44
IFX: infliximab, CR: clinical remission, CRP: C-reactive protein.
Result reported as number (%) of patients or *mean ± standard deviation.
Yamada et al. BMC Gastroenterology 2014, 14:80 Page 7 of 9
http://www.biomedcentral.com/1471-230X/14/80in patients with inflammatory bowel disease [23-25], with
CRP being a particularly sensitive marker in UC patients.
Thus, early reduction of serum CRP may be a useful
marker for evaluating the efficacy of IFX treatment.
CMV reactivation in inflamed mucosa may contribute to
the exacerbation of UC [26,27]. However, the therapeutic
effects of anti-viral treatment of UC patients with CMV re-
activation have not been evaluated because virological cri-
teria identifying patients who require anti-viral treatment
have not been established. We found that the remissionTable 5 Demographic and clinical characteristics of the respo
Characteristics Responders with CMV infec
Sex (men/women), n (%) 4 (66.7)/2 (33.3)
Age (years)* 50.8 ± 16.2
Disease duration (years)* 4.5 ± 4.8
Modified Truelove and Witts severity index* 8.3 ± 1.7
Mayo score (endoscopy)* 2.8 ± 0.4
Extent of disease
Left-side type, n (%) 2 (33.3)
Extensive colitis, n (%) 4 (66.7)
Concomitant medications
Corticoteroids, n (%) 0 (0.0)
Azathioprine/Mercaptopurine, n (%) 3 (50.0)
Tacrolimus, n (%) 1 (16.7)
IFX: infliximab, CR: clinical remission, CRP: C-reactive protein.
Result reported as number (%) of patients or *mean ± standard deviation.rate was lower in UC patients with CMV reactivation than
in CMV-negative patients, suggesting a reduction of CMV
reactivation in the colonic mucosa may affect the efficacy
of immunomodulatory treatment. Although responses to
IFX therapy were reported unaffected by HCMV infection/
disease [28], an algorithm for the management of CMV re-
activation includes antiviral treatment in IBD patients with
high CMV load in tissue (>250 copies/mg) [29]. Thus, fur-
ther studies are required to determine the effects of CMV
infection on UC patients treated with IFX.nders and non-responders of IFX with CMV infection
tion (n = 6) Non-responders with CMV infection (n = 5) p value
2 (40.0)/3 (60.0) 0.38
41.4 ± 17.2 0.42
10.2 ± 9.6 0.32
12.4 ± 2.2 0.02
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in patient with UC [5,7,30], with the percentages of pa-
tients achieving mucosal healing in response to IFX ran-
ging from 45 to 53%, and 43% in refractory UC patients
[7]. We observed mucosal healing in 76.5% (13/17) of UC
patients receiving IFX maintenance treatment, includ-
ing IFX intensification. Thus, the ability of IFX intensifi-
cation to enhance mucosal healing rates suggests a
favorable clinical outcome.
The present study has several limitations. First, muco-
sal healing was not evaluated by colonoscopy in all en-
rolled patients, and mucosal healing assessment time
varied widely. In addition, multivariate analysis could
not be performed to identify factors predicting the need
for IFX intensification because of the small number of pa-
tients enrolled in the study. Furthermore, some treatments
drugs available in Japan to moderate or severe UC are not
available in western countries including cytapheresis, ta-
crolimus, adalimumab and IFX. Finally, this study was a
single center analysis, suggesting the need for larger, mul-
ticenter studies to evaluate the effects of long-term IFX
treatment in patients with refractory UC.
Conclusions
In conclusion, we found that 64.8% of our patients with
refractory UC avoided colectomy by receiving IFX treat-
ment. IFX was more effective when given in combination
with thiopurines than when administered as monotherapy.
IFX-intensification treatment, however, was required by
70.8% of UC patients. IFX dose should be tailored to indi-
vidual patients, based on factors baseline serum TNF-α
concentration, in the treatment of refractory UC.
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